- Home
- EEA vs BMEA Comparison
EEA vs BMEA Comparison
Compare EEA & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EEA
- BMEA
- Stock Information
- Founded
- EEA 1986
- BMEA 2017
- Country
- EEA Germany
- BMEA United States
- Employees
- EEA N/A
- BMEA N/A
- Industry
- EEA Trusts Except Educational Religious and Charitable
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- EEA Finance
- BMEA Health Care
- Exchange
- EEA Nasdaq
- BMEA Nasdaq
- Market Cap
- EEA 67.9M
- BMEA 65.8M
- IPO Year
- EEA N/A
- BMEA 2021
- Fundamental
- Price
- EEA $10.68
- BMEA $1.73
- Analyst Decision
- EEA
- BMEA Strong Buy
- Analyst Count
- EEA 0
- BMEA 10
- Target Price
- EEA N/A
- BMEA $17.70
- AVG Volume (30 Days)
- EEA 9.2K
- BMEA 772.9K
- Earning Date
- EEA 01-01-0001
- BMEA 08-05-2025
- Dividend Yield
- EEA 1.92%
- BMEA N/A
- EPS Growth
- EEA N/A
- BMEA N/A
- EPS
- EEA N/A
- BMEA N/A
- Revenue
- EEA N/A
- BMEA N/A
- Revenue This Year
- EEA N/A
- BMEA N/A
- Revenue Next Year
- EEA N/A
- BMEA N/A
- P/E Ratio
- EEA N/A
- BMEA N/A
- Revenue Growth
- EEA N/A
- BMEA N/A
- 52 Week Low
- EEA $7.45
- BMEA $1.29
- 52 Week High
- EEA $9.26
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- EEA 71.63
- BMEA 50.34
- Support Level
- EEA $10.33
- BMEA $1.51
- Resistance Level
- EEA $10.40
- BMEA $1.74
- Average True Range (ATR)
- EEA 0.15
- BMEA 0.10
- MACD
- EEA 0.04
- BMEA 0.02
- Stochastic Oscillator
- EEA 87.84
- BMEA 74.19
About EEA The European Equity Fund Inc.
European Equity Fund, Inc / MD is a United States-based diversified, closed-end management investment company. The fund seeks long-term capital appreciation through investment in equity and equity securities of issuers domiciled in Europe. Its portfolio of investments consists of different sectors such as industrials, financials, healthcare, consumer discretionary, materials, consumer staples, information technology, and other sectors.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.